Karin Jooss
Technik-/Wissenschafts-/F&E-Leiter bei GRITSTONE BIO, INC.
Vermögen: 340 443 $ am 30.04.2024
Aktive Positionen von Karin Jooss
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| GRITSTONE BIO, INC. | Technik-/Wissenschafts-/F&E-Leiter | 13.04.2016 | - |
| FATE THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 14.03.2019 | - |
| Independent Dir/Board Member | 14.03.2019 | - |
Karriereverlauf von Karin Jooss
Ehemalige bekannte Positionen von Karin Jooss
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | 01.05.2009 | 01.04.2016 |
Cell Genesys, Inc.
 Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2001 | 01.04.2009 |
Ausbildung von Karin Jooss
| Philipps University of Marburg | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 5 |
| Deutschland | 2 |
Operativ
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 5 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| GRITSTONE BIO, INC. | Health Technology |
| PFIZER, INC. | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
- Börse
- Insiders
- Karin Jooss
- Erfahrung
